MabVax Therapeutics Holdings Inc. regained compliance with the Nasdaq Capital Market's minimum bid price requirement.
The closing bid price of MabVax common stock had been at $1 per share or more for at least 10 days before the March 5 deadline for continued listing.
The San Diego-based company was able to maintain the minimum price as a result of its 1-to-3 reverse stock split.
The biotechnology company, developing treatments for cancer, previously regained compliance with Nasdaq's minimum equity requirement after raising $4.8 million during the third quarter of 2017.
